Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
32 hedge funds and large institutions have $3.86M invested in Biostage, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
14% less funds holding
Funds holding: 37 → 32 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
64% less capital invested
Capital invested by funds: $10.6M → $3.86M (-$6.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$226K |
| 2 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
+$122K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$85.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$53.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$652K |
| 2 |
SCM
Sio Capital Management
New York
|
-$547K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$318K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$260K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$163K |
BSTG Hedge Fund Activity: Q2 2015 in Review
32 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q2 2015, worth a combined $3.86M — down 64% from $10.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BSTG and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $226K. The largest seller was 683 Capital Management, exiting entirely with an estimated $652K sold.
- 32 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q2 2015, down from 37 in Q1 2015.
- Funds reported $3.86M of Biostage, Inc. Common Stock stock for Q2 2015, down 64% quarter-over-quarter.
- 3 funds opened new Biostage, Inc. Common Stock positions in Q2 2015 and 8 closed out, a net change of -5 holders.
- The largest Biostage, Inc. Common Stock buyer in Q2 2015 was Renaissance Technologies, an estimated $226K added.
- The largest Biostage, Inc. Common Stock seller in Q2 2015 was 683 Capital Management, an estimated $652K sold.
Based on aggregated 13F filings for Q2 2015.